Impact of the SARS-CoV-2 Pandemic on the Prevalence and Incidence of Enteric Protozoa in a Spanish Tertiary-Care Hospital and a Referral Center for Tropical Diseases, 2019-2023.
Alfredo Maldonado-Barrueco, Fernando de la Calle-Prieto, Marta Díaz-Menéndez, Marta Arsuaga, Julio García-Rodríguez, Guillermo Ruiz-Carrascoso
{"title":"Impact of the SARS-CoV-2 Pandemic on the Prevalence and Incidence of Enteric Protozoa in a Spanish Tertiary-Care Hospital and a Referral Center for Tropical Diseases, 2019-2023.","authors":"Alfredo Maldonado-Barrueco, Fernando de la Calle-Prieto, Marta Díaz-Menéndez, Marta Arsuaga, Julio García-Rodríguez, Guillermo Ruiz-Carrascoso","doi":"10.3390/medsci13010023","DOIUrl":null,"url":null,"abstract":"<p><strong>Objetive: </strong>The aim of this study was to describe the impact of non-pharmaceutical interventions (NPIs) against SARS-CoV-2 in patients with symptoms of enteric protozoa (EP), including <i>Blastocystis</i> spp., <i>Dientamoeba fragilis</i>, <i>Giardia lamblia</i>, <i>Cryptosporidium</i> spp., <i>Entamoeba histolytica</i>, and <i>Cyclospora cayetanensis</i>, in the overall population and in patients who were consulted at a National Referral Center for Imported Tropical Diseases (NRCITD patients) from a healthcare area in Madrid (Spain).</p><p><strong>Method: </strong>Data on patients with positive RT-PCR results for EP were collected. The periods analyzed were prepandemic (P0, 1 April 2019-31 March 2020), and the first (P1, 1 April 2020-31 March 2021), second (P2, 1 April 2021-31 March 2022), and third (P3, 1 April 2022-31 March 2023) pandemic years. We compared the prevalence, median age, absolute incidence (EP per 100,000 population of each period), and patient profile (NRCITD vs. non-NRCITD) during the study periods using Fisher's test (<i>p</i> < 0.05) and the T-test (<i>p</i> < 0.001).</p><p><strong>Results: </strong>During P0, 24.8%, [95% CI: 23.9-25.6] of patients tested for EP RT-PCR were positive, 22.6% [95% CI: 21.5-23.7] were positive in P1, 20.4%, [95% CI: 19.5-21.3] were positive during P2, and 20% [95% CI: 19.2-20.9] of patients tested during P3 were positive. During the study, there was no difference in the median ages. The prevalence and absolute incidence of EP showed a decreasing trend during the pandemic for the NRCITD and non-NRCITD patients (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong><i>Blastocystis</i> spp. and <i>D. fragilis</i> showed a lower decrease in prevalence during P1 (<i>p</i> > 0.05) due to the higher detection of colonized patients during the SARS-CoV-2 pandemic. However, <i>G. lamblia</i> and <i>Cryptosporidium</i> spp. showed the highest decrease in prevalence and absolute incidence during P2 (<i>p</i> < 0.05) because of the NPIs implemented during the SARS-CoV-2 pandemic. The NTRCID patients showed a higher prevalence of <i>Blastocystis</i> spp. than the non-NTRCID patients during every period studied (<i>p</i> < 0.001). <i>E. histolytica</i> and <i>C. cayetanensis</i> showed a homogeneous trend.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943737/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical sciences (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medsci13010023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objetive: The aim of this study was to describe the impact of non-pharmaceutical interventions (NPIs) against SARS-CoV-2 in patients with symptoms of enteric protozoa (EP), including Blastocystis spp., Dientamoeba fragilis, Giardia lamblia, Cryptosporidium spp., Entamoeba histolytica, and Cyclospora cayetanensis, in the overall population and in patients who were consulted at a National Referral Center for Imported Tropical Diseases (NRCITD patients) from a healthcare area in Madrid (Spain).
Method: Data on patients with positive RT-PCR results for EP were collected. The periods analyzed were prepandemic (P0, 1 April 2019-31 March 2020), and the first (P1, 1 April 2020-31 March 2021), second (P2, 1 April 2021-31 March 2022), and third (P3, 1 April 2022-31 March 2023) pandemic years. We compared the prevalence, median age, absolute incidence (EP per 100,000 population of each period), and patient profile (NRCITD vs. non-NRCITD) during the study periods using Fisher's test (p < 0.05) and the T-test (p < 0.001).
Results: During P0, 24.8%, [95% CI: 23.9-25.6] of patients tested for EP RT-PCR were positive, 22.6% [95% CI: 21.5-23.7] were positive in P1, 20.4%, [95% CI: 19.5-21.3] were positive during P2, and 20% [95% CI: 19.2-20.9] of patients tested during P3 were positive. During the study, there was no difference in the median ages. The prevalence and absolute incidence of EP showed a decreasing trend during the pandemic for the NRCITD and non-NRCITD patients (p < 0.05).
Conclusion: Blastocystis spp. and D. fragilis showed a lower decrease in prevalence during P1 (p > 0.05) due to the higher detection of colonized patients during the SARS-CoV-2 pandemic. However, G. lamblia and Cryptosporidium spp. showed the highest decrease in prevalence and absolute incidence during P2 (p < 0.05) because of the NPIs implemented during the SARS-CoV-2 pandemic. The NTRCID patients showed a higher prevalence of Blastocystis spp. than the non-NTRCID patients during every period studied (p < 0.001). E. histolytica and C. cayetanensis showed a homogeneous trend.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
